Description

The EORTC Brain Tumor Group (BTG) initiates and conducts academic clinical trials in patients with brain tumours, as well as designing and completing translational research associated with these trials. Its strategy is to challenge, re-define and develop standards of care in all controversial areas of diagnostic and therapeutic Neuro-Oncology, with a focus on diffuse gliomas of adulthood of WHO grades II to IV and, in recent years, also meningioma. The BTG has created several subcommittees that help design and conduct its scientific projects and cover key aspects of all projects such as imaging, translational research, quality of life, and quality assurance. The BTG is open for cooperative projects involving other EORTC groups as well external cooperation, for example with Neuro-Oncology networks in Canada, Australia and the US. The group aims to recruit and mentor junior European colleagues from all involved disciplines who are interested in pursuing an academic career in Neuro-Oncology.

Main Achievements

In 2005, an EORTC-led trial defined the current standard of care of temozolomide chemoradiotherapy for patients with newly diagnosed glioblastoma. (More information)

A translational research study linked to this trial established O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status as a predictive biomarker for benefit from temozolomide chemotherapy. DOI

In 2014, long-term follow-up of EORTC 26951 demonstrated that PCV polychemotherapy after radiotherapy improved progression-free and overall survival in anaplastic oligodendroglial tumours with 1p/19q codeletion (More information)

In 2016, the CATNON trial demonstrated that maintenance temozolomide prolongs survival in patients with 1p/19q-non-codeleted anaplastic gliomas. (More information)

In 2016, a trial performed in partnership with Canada Cancer Clinical Trial Group, in elderly patients, confirmed the added benefit of temozolomide based chemoradiotherapy.

Also in 2016, in the Lancet Oncology, two papers revealed that there were no significant differences in Progression-Free Survival (PFS) (more information), Health-Related Quality of Life (HRQOL) (more information) and cognitive function in patients with low-grade glioma who were treated with either standard radiotherapy or primary chemotherapy.

Related Projects

  • SPECTAbrain: The aim of SPECTAbrain is to collect tumour specimens from patients with brain tumours for detailed molecular characterisation. This offers multiple opportunities to investigate the biology of brain tumours and to allocate eligible patients to biomarker-driven therapeutic clinical trials.
  • 1230: Prognostic factor analysis in elderly GBM. Development of the model in Nordic and NOA 8 and validation in EORTC 26062/NCCTG CE.6 trial.
    (project leader: Annika Malmstrom)
    Analyses ongoing.
  • 1337: Secondary analysis of the impact of extended adjuvant temozolomide in newly-diagnosed glioblastoma.
    (project leaders: Deborah Blumenthal & Roger Stupp)
    The publication has been accepted in Neuro-Oncology.
  • 1426: Prognostic effect of the use of statins, ACE and sartanes in newly diagnosed glioblastoma
    (project leader: Caroline Happold)
    Publication in preparation.
  • 1542 (G-SAM): Stability of actionable mutations in glioblastoma
    (project leader: Pim French)
    Genomic analyses ongoing.
  • 1632 (ANTICOA-GBM): Retrospective evaluation of the effect of anticoagulants during initial treatment on survival and safety in glioblastoma patients
    (project leader: Emilie Le Rhun)
    Analyses ongoing
  • 1654: Meta-analysis of the correlation between MGMT promoter methylation data and survival outcome after chemoratiotherapy (TMZ/RT /TMZ) for newly diagnosed glioblastoma
    (project leader: Michael Weller)
    Pending for complete data collection.
  • 1661 (GLIOMAG II/III PANEL): Construction of an integrated diagnostic algorithm consisting of consensus histology and molecular parameters using the pathology slides of CATNON and the low-grade glioma study
    (project leader: Max Kros)
    Pending for complete data collection.
  • 1662 (JBTDDC): Jumpstarting Brain Tumor Drug Development Coalition (JBTDDC); MRI Image Analysis Workgroup
    (project leader: Michael Weller)
    Pending for DTA signature.
  • 1663 (Metformin-GBM): Associate of metformin use with outcome in IDH1-mutant vs IDH1-Wildtype gliomas of WHO Grades II-IV
    (project leader: Peter Hau)
    Analyses ongoing.
  • 1664 (TMT-Gliomas): Evaluation of temporal muscle thickness as prognostic parameter in glioma patients: retrospective imaging study in TAVAREC 26091 and EORTC 26101
    (project leader: Matthias Preusser)
    Pending for CDA signature.
  • 1665 (Antidepressant): Potential prognostic effect of tricyclic antidepressants in patients with newly diagnosed glioblastoma.
    (project leader: Florence Lefranc)
    Analyses ongoing.

Research Group

Group documents
  • Chair

    Michael Weller

    Universitätsspital Zürich

    Zurich, Switzerland

  • Secretary

    Jaap Reijneveld

    Vrije Universiteit Medisch Centrum

    Amsterdam, Netherlands

  • Treasurer

    Frédéric Dhermain

    Institut Gustave Roussy

    Villejuif, France

Test

  • J. Reijneveld - Amsterdam, NL

    Vrije Universiteit Medisch Centrum

Test

  • J. Reijneveld - Amsterdam, NL

    Vrije Universiteit Medisch Centrum